{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T03:14:04Z","timestamp":1770261244743,"version":"3.49.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015382","name":"The University of British Columbia Centre for Blood Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.leukres.2026.108171","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:56:20Z","timestamp":1769010980000},"page":"108171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Calcium channel blocker use is associated with longer time to first post transfusion cardiac event in lower risk MDS"],"prefix":"10.1016","volume":"161","author":[{"given":"Carissa S.Y.","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7899-2025","authenticated-orcid":false,"given":"Heather A.","family":"Leitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.leukres.2026.108171_bib1","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/cncr.22570","article-title":"Myelodysplastic syndromes: incidence and survival in the United States","volume":"109","author":"Ma","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2026.108171_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3324\/haematol.2017.171884","article-title":"Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes","volume":"103","author":"de Swart","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2026.108171_bib3","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3324\/haematol.2022.280723","article-title":"High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes","volume":"108","author":"Teichman","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2026.108171_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood.2023022501","article-title":"How I treat iron overload in adult MDS","volume":"145","author":"Leitch","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2026.108171_bib5","doi-asserted-by":"crossref","first-page":"C862","DOI":"10.1152\/ajpcell.00479.2010","article-title":"Zip14 is a complex broad-scope metal-ion transporter whose functional properties support roles in the cellular uptake of zinc and nontransferrin-bound iron","volume":"301","author":"Pinilla-Tenas","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108171_bib6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/jn\/nxx041","article-title":"The multiple faces of the metal transporter ZIP14 (SLC39A14)","volume":"148","author":"Aydemir","year":"2018","journal-title":"J. Nutr."},{"issue":"5","key":"10.1016\/j.leukres.2026.108171_bib7","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00277-014-2274-y","article-title":"G; IRON-2 Study Group. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications","volume":"94","author":"Remacha","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2026.108171_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106170","article-title":"Delayed time from RBC transfusion dependence to first cardiac event in lower IPSS risk MDS patients receiving iron chelation therapy","volume":"83","author":"Wong","year":"2019","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.leukres.2026.108171_bib9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M19-0916","article-title":"Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes: a randomized trial","volume":"172","author":"Angelucci","year":"2022","journal-title":"Ann. Intern. Med."},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2026.108171_bib10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2021-154296","article-title":"Metal-ion transporter SLC39A14 is required for cardiac iron loading in the hjv mouse model of iron overload","volume":"138","author":"Liu","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2026.108171_bib11","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2026.108171_bib12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1158\/2159-8290.CD-24-0719","article-title":"Nonselective beta-adrenergic receptor inhibitors impair hematopoietic regeneration in mice and humans after hematopoietic cell transplants","volume":"15","author":"Nishino","year":"2025","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.leukres.2026.108171_bib13","article-title":"Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia","volume":"11","author":"Padhani","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.leukres.2026.108171_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29564","article-title":"Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: a randomized double-blind placebo-controlled trial","volume":"69","author":"Gupta","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"issue":"12","key":"10.1016\/j.leukres.2026.108171_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005360","article-title":"Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial","volume":"4","author":"Shakoor","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.leukres.2026.108171_bib16","doi-asserted-by":"crossref","unstructured":"Leitch H.A., Gattermann N. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions. Crit Rev Oncol Hematol. 2019:141:54-72. doi: 10.1016\/j.critrevonc.2019.06.002. Epub 2019 Jun 10. PMID: 31228649 DOI: 10.1016\/j.critrevonc.2019.06.002.","DOI":"10.1016\/j.critrevonc.2019.06.002"},{"issue":"9","key":"10.1016\/j.leukres.2026.108171_bib17","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3324\/haematol.2011.048546","article-title":"Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes","volume":"97","author":"Gattermann","year":"2012","journal-title":"Haematologica"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T13:48:54Z","timestamp":1770212934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":17,"alternative-id":["S0145212626000159"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108171","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcium channel blocker use is associated with longer time to first post transfusion cardiac event in lower risk MDS","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108171","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108171"}}